Acneiform Eruption Induced by Dacomitinib (PF-00299804) / 대한피부과학회지
Korean Journal of Dermatology
;
: 324-327, 2015.
Artigo
em Coreano
| WPRIM
| ID: wpr-135048
ABSTRACT
Dacomitinib (PF-00299804) is a newly developed irreversible pan-HER (human epidermal growth factor receptor) inhibitor for the treatment of non-small cell lung cancer (NSCLC). Inhibiting HER-1 (epidermal growth factor receptor, EGFR), HER-2, and HER-4 may induce similar cutaneous side effects to those of traditional EGFR inhibitors. We report two patients who developed acneiform eruption on the face and trunk, induced by dacomitinib treatment for NSCLC. The skin lesions appeared 3~4 weeks after the initiation of dacomitinib use, and they improved after oral minocycline and topical clindamycin treatment. There has been no report of acneiform eruption after dacomitinib treatment in Korean dermatology journals.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Pele
/
Clindamicina
/
Erupções Acneiformes
/
Carcinoma Pulmonar de Células não Pequenas
/
Dermatologia
/
Tratamento Farmacológico
/
Fator de Crescimento Epidérmico
/
Minociclina
Limite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Dermatology
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS